



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com


www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



Laduviglusib monohydrochloride

Cat. No.: HY-10182A
CAS No.: 1797989-42-4
Molecular Formula: C₂₂H₁₉Cl₃N₈
Molecular Weight: 501.8
Storage: 4°C, sealed storage, away from moisture
 * In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 60 mg/mL (119.57 mM; Need ultrasonic)
 H₂O : 7.14 mg/mL (14.23 mM; Need ultrasonic)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		1.9928 mL	9.9641 mL	19.9283 mL
	5 mM		0.3986 mL	1.9928 mL	3.9857 mL
	10 mM		0.1993 mL	0.9964 mL	1.9928 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: PBS
Solubility: 5 mg/mL (9.96 mM); Clear solution; Need ultrasonic
2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 3 mg/mL (5.98 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 3 mg/mL (5.98 mM); Clear solution
4. Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 3 mg/mL (5.98 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Laduviglusib (CHIR-99021) monohydrochloride is a potent and selective GSK-3α/β inhibitor with IC₅₀s of 10 nM and 6.7 nM. Laduviglusib monohydrochloride shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib monohydrochloride is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib monohydrochloride enhances mouse and human embryonic stem cells self-renewal. Laduviglusib monohydrochloride induces autophagy^{[1][2][3]}.

IC₅₀ & Target	IC50: 10 nM/6.7 nM (GSK-3α/β) ^[1]
In Vitro	Laduviglusib monohydrochloride inhibits human GSK-3β with K _i values of 9.8 nM ^[1] . Laduviglusib monohydrochloride is a small organic molecule that inhibits GSK3α and GSK3β by competing for their ATP-binding sites. In vitro kinase assays reveal that Laduviglusib monohydrochloride specifically inhibits GSK3β (IC ₅₀ ≈5 nM) and GSK3α (IC ₅₀ ≈10 nM), with little effect on other kinases ^[4] . In the presence of Laduviglusib monohydrochloride the viability of the ES-D3 cells is reduced by 24.7% at 2.5 μM, 56.3% at 5 μM, 61.9% at 7.5 μM and 69.2% at 10 μM Laduviglusib monohydrochloride with an IC ₅₀ of 4.9 μM ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	In ZDF rats, a single oral dose of Laduviglusib (16 mg/kg or 48 mg/kg) monohydrochloride rapidly lowers plasma glucose, with a maximal reduction of nearly 150 mg/dl 3-4 h after administration ^[1] . Laduviglusib (2 mg/kg) monohydrochloride given once, 4 h before irradiation, significantly improves survival after 14.5 Gy abdominal irradiation (ABI). Laduviglusib monohydrochloride treatment significantly blocks crypt apoptosis and accumulation of p-H2AX ⁺ cells, and improves crypt regeneration and villus height. Laduviglusib monohydrochloride treatment increases Lgr5 ⁺ cell survival by blocking apoptosis, and effectively prevents the reduction of Olfm4, Lgr5 and CD44 as early as 4 h ^[5] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Cell Assay ^[3]	The viability of the mouse ES cells is determined after exposure to different concentrations of GSK3 inhibitors for three days using the MTT assay. The decrease of MTT activity is a reliable metabolism-based test for quantifying cell viability; this decrease correlates with the loss of cell viability. 2,000 cells are seeded overnight on gelatine-coated 96-well plates in LIF-containing ES cell medium. On the next day the medium is changed to medium devoid of LIF and with reduced serum and supplemented with 0.1-1 μM BIO, or 1-10 μM SB-216763, CHIR-99021 or CHIR-98014. Basal medium without GSK3 inhibitors or DMSO is used as control. All tested conditions are analyzed in triplicates ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^{[1][4]}	<p>Rats^[1]</p> <p>Primary hepatocytes from male Sprague Dawley rats that weighed <140 g are prepared and used 1-3 h after isolation. Aliquots of 1×10⁶ cells in 1 mL of DMEM/F12 medium plus 0.2% BSA and CHIR-99021 (orally at 16 or 48 mg/kg) or controls are incubated in 12-well plates on a low-speed shaker for 30 min at 37°C in a CO₂-enriched atmosphere, collected by centrifugation and lysed by freeze/thaw in buffer A plus 0.01% NP40; the GS assay is again performed.</p> <p>Mice^[4]</p> <p>Mice 6-10 weeks old are used. The PUMA^{+/+} and PUMA^{-/-} littermates on C57BL/6 background (F10) and Lgr5-EGFP (Lgr5-EGFP-IRES-creERT2) mice are subjected to whole body irradiation (TBI), or abdominal irradiation (ABI). Mice are injected intraperitoneally (i.p.) with 2 mg/kg of CHIR99021 4 h before radiation or 1 mg/kg of SB415286 28 h and 4 h before radiation. Mice are sacrificed to collect small intestines for histology analysis and western blotting. All mice are injected i.p. with 100 mg/kg of BrdU before sacrifice.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

CUSTOMER VALIDATION

- Nat Med. 2016 May;22(5):547-56.
- Cell Discov. 2023 Jun 6;9(1):53.
- Nat Genet. 2024 Jan 24.
- Cell Stem Cell. 2022 Sep 1;29(9):1366-1381.e9.
- Cell Stem Cell. 2022 Jul 7;29(7):1102-1118.e8.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA